Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

The anticancer agent 3-bromopyruvate: a simple but powerful molecule taken from the lab to the bedside.

Azevedo-Silva J, Queirós O, Baltazar F, Ułaszewski S, Goffeau A, Ko YH, Pedersen PL, Preto A, Casal M.

J Bioenerg Biomembr. 2016 Aug;48(4):349-62. doi: 10.1007/s10863-016-9670-z. Epub 2016 Jul 25. Review.

PMID:
27457582
2.

A translational study "case report" on the small molecule "energy blocker" 3-bromopyruvate (3BP) as a potent anticancer agent: from bench side to bedside.

Ko YH, Verhoeven HA, Lee MJ, Corbin DJ, Vogl TJ, Pedersen PL.

J Bioenerg Biomembr. 2012 Feb;44(1):163-70. doi: 10.1007/s10863-012-9417-4. Epub 2012 Feb 11.

PMID:
22328020
3.
5.

Safety and outcome of treatment of metastatic melanoma using 3-bromopyruvate: a concise literature review and case study.

El Sayed SM, Mohamed WG, Seddik MA, Ahmed AS, Mahmoud AG, Amer WH, Helmy Nabo MM, Hamed AR, Ahmed NS, Abd-Allah AA.

Chin J Cancer. 2014 Jul;33(7):356-64. doi: 10.5732/cjc.013.10111. Epub 2014 Mar 14. Review.

6.

The promising anticancer drug 3-bromopyruvate is metabolized through glutathione conjugation which affects chemoresistance and clinical practice: An evidence-based view.

El Sayed SM, Baghdadi H, Zolaly M, Almaramhy HH, Ayat M, Donki JG.

Med Hypotheses. 2017 Mar;100:67-77. doi: 10.1016/j.mehy.2017.01.014. Epub 2017 Jan 23.

PMID:
28236852
7.

Flow cytometric evaluation of the effects of 3-bromopyruvate (3BP) and dichloracetate (DCA) on THP-1 cells: a multiparameter analysis.

Verhoeven HA, van Griensven LJ.

J Bioenerg Biomembr. 2012 Feb;44(1):91-9. doi: 10.1007/s10863-012-9414-7. Epub 2012 Feb 9.

PMID:
22318358
8.

3-Bromopyruvate antagonizes effects of lactate and pyruvate, synergizes with citrate and exerts novel anti-glioma effects.

El Sayed SM, El-Magd RM, Shishido Y, Chung SP, Diem TH, Sakai T, Watanabe H, Kagami S, Fukui K.

J Bioenerg Biomembr. 2012 Feb;44(1):61-79. doi: 10.1007/s10863-012-9409-4. Epub 2012 Feb 9.

PMID:
22318356
9.

The HK2 Dependent "Warburg Effect" and Mitochondrial Oxidative Phosphorylation in Cancer: Targets for Effective Therapy with 3-Bromopyruvate.

Lis P, Dyląg M, Niedźwiecka K, Ko YH, Pedersen PL, Goffeau A, Ułaszewski S.

Molecules. 2016 Dec 15;21(12). pii: E1730. Review.

10.

Bioorthogonal Profiling of a Cancer Cell Proteome Identifies a Large Set of 3-Bromopyruvate Targets beyond Glycolysis.

Darabedian N, Chen TC, Molina H, Pratt MR, Schönthal AH.

ACS Chem Biol. 2018 Nov 16;13(11):3054-3058. doi: 10.1021/acschembio.8b00743. Epub 2018 Nov 7.

PMID:
30395437
11.

3-Bromopyruvate as a potent anticancer therapy in honor and memory of the late Professor André Goffeau.

Ko YH, Niedźwiecka K, Casal M, Pedersen PL, Ułaszewski S.

Yeast. 2019 Apr;36(4):211-221. doi: 10.1002/yea.3367. Epub 2018 Dec 13.

PMID:
30462852
12.

Topical 3-bromopyruvate is a novel targeted therapy for melanoma in a preclinical model.

Yamada M, Kagaya M, Noguchi N, Ueki S, Hasunuma N, Osada SI, Manabe M.

J Dermatol Sci. 2018 Nov;92(2):134-142. doi: 10.1016/j.jdermsci.2018.08.009. Epub 2018 Aug 30.

PMID:
30206027
13.

The energy blockers 3-bromopyruvate and lonidamine: effects on bioenergetics of brain mitochondria.

Macchioni L, Davidescu M, Roberti R, Corazzi L.

J Bioenerg Biomembr. 2014 Oct;46(5):389-94. doi: 10.1007/s10863-014-9577-5. Epub 2014 Sep 7.

PMID:
25194986
14.

Anticancer efficacy of the metabolic blocker 3-bromopyruvate: specific molecular targeting.

Ganapathy-Kanniappan S, Kunjithapatham R, Geschwind JF.

Anticancer Res. 2013 Jan;33(1):13-20. Review.

PMID:
23267123
15.

3-Bromopyruvate treatment induces alterations of metabolic and stress-related pathways in glioblastoma cells.

Chiasserini D, Davidescu M, Orvietani PL, Susta F, Macchioni L, Petricciuolo M, Castigli E, Roberti R, Binaglia L, Corazzi L.

J Proteomics. 2017 Jan 30;152:329-338. doi: 10.1016/j.jprot.2016.11.013. Epub 2016 Nov 24.

PMID:
27890797
16.

Targeting aerobic glycolysis: 3-bromopyruvate as a promising anticancer drug.

Cardaci S, Desideri E, Ciriolo MR.

J Bioenerg Biomembr. 2012 Feb;44(1):17-29. doi: 10.1007/s10863-012-9422-7. Review.

PMID:
22328057
17.

Mitochondria: 3-bromopyruvate vs. mitochondria? A small molecule that attacks tumors by targeting their bioenergetic diversity.

Galina A.

Int J Biochem Cell Biol. 2014 Sep;54:266-71. doi: 10.1016/j.biocel.2014.05.013. Epub 2014 May 16.

PMID:
24842108
18.

The cytotoxicity of 3-bromopyruvate in breast cancer cells depends on extracellular pH.

Azevedo-Silva J, Queirós O, Ribeiro A, Baltazar F, Young KH, Pedersen PL, Preto A, Casal M.

Biochem J. 2015 Apr 15;467(2):247-58. doi: 10.1042/BJ20140921.

PMID:
25641640
19.

Glutathione may have implications in the design of 3-bromopyruvate treatment protocols for both fungal and algal infections as well as multiple myeloma.

Niedźwiecka K, Dyląg M, Augustyniak D, Majkowska-Skrobek G, Cal-Bąkowska M, Ko YH, Pedersen PL, Goffeau A, Ułaszewski S.

Oncotarget. 2016 Oct 4;7(40):65614-65626. doi: 10.18632/oncotarget.11592.

20.

D-Amino acid oxidase-induced oxidative stress, 3-bromopyruvate and citrate inhibit angiogenesis, exhibiting potent anticancer effects.

El Sayed SM, El-Magd RM, Shishido Y, Yorita K, Chung SP, Tran DH, Sakai T, Watanabe H, Kagami S, Fukui K.

J Bioenerg Biomembr. 2012 Oct;44(5):513-23. doi: 10.1007/s10863-012-9455-y. Epub 2012 Jul 17.

PMID:
22802136

Supplemental Content

Support Center